Company intelligence / Profile preview

Numa Biosciences

Bothell, Washington, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Numa Biosciences (formerly known as Nortis, merged with Biosystics) developed organ-on-chip technologies featuring microfluidic devices and functional human tissue models. Their ParVivo system was used for in-vitro testing and in drug development, including space research. The company specialized in human tissue models on microfluidic chips for kidney, brain, heart, liver, immune, vascular, and cancer. As of 2024, the company and website appear dormant/offline.

Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Numa Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Numa Biosciences.

Explore the full profile